Eng Huat Tan

12.7k total citations · 3 hit papers
55 papers, 6.8k citations indexed

About

Eng Huat Tan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Eng Huat Tan has authored 55 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 34 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Eng Huat Tan's work include Lung Cancer Treatments and Mutations (36 papers), Lung Cancer Research Studies (17 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Eng Huat Tan is often cited by papers focused on Lung Cancer Treatments and Mutations (36 papers), Lung Cancer Research Studies (17 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Eng Huat Tan collaborates with scholars based in Singapore, United States and Germany. Eng Huat Tan's co-authors include Sumitra Thongprasert, Vera Hirsh, Tudor–Eliade Ciuleanu, B. Findlay, Mircea Dediu, Daniel de Castro, Michael Smylie, Maximiliano Van Kooten, José Rodrigues Pereira and Andrea Bezjak and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Eng Huat Tan

54 papers receiving 6.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 4.3k citations Tudor–Eliade Ciuleanu, Eng Huat Tan et al. profile →
Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer/International Union Against Cancer Stage III and IV Nasopharyngeal Cancer of the Endemic Variety

2005 496 citations Joseph Wee, Eng Huat Tan et al. profile →
Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

2013 383 citations Vera Hirsh, Sumitra Thongprasert et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Eng Huat Tan	4.7k	4.6k	1.7k	1.0k	732	55	6.8k
Junming Zhu	4.3k 0.9×	4.1k 0.9×	1.8k 1.1×	879 0.8×	941 1.3×	29	7.3k
Philip Bonomi	4.4k 0.9×	4.9k 1.1×	2.1k 1.3×	978 0.9×	648 0.9×	241	8.0k
Serban Ghiorghiu	5.1k 1.1×	4.0k 0.9×	1.8k 1.1×	1.4k 1.3×	297 0.4×	30	5.9k
A. Harstrick	2.9k 0.6×	5.6k 1.2×	1.9k 1.1×	702 0.7×	1.8k 2.4×	128	8.2k
Mark Kozloff	1.7k 0.4×	3.2k 0.7×	1.3k 0.8×	702 0.7×	612 0.8×	125	4.7k
Luis E. Raez	1.7k 0.4×	2.2k 0.5×	1.8k 1.1×	1.2k 1.1×	573 0.8×	224	4.6k
Wilfried Eberhardt	5.3k 1.1×	4.2k 0.9×	1.7k 1.0×	892 0.9×	559 0.8×	239	7.6k
Otilia Dalesio	3.9k 0.8×	4.4k 1.0×	1.5k 0.9×	1.0k 1.0×	1.4k 2.0×	104	8.0k
Shinzoh Kudoh	4.5k 1.0×	4.0k 0.9×	1.3k 0.8×	489 0.5×	310 0.4×	84	5.7k
P. Koralewski	3.5k 0.7×	4.5k 1.0×	2.1k 1.2×	1.7k 1.7×	926 1.3×	58	7.1k

Countries citing papers authored by Eng Huat Tan

Since Specialization

Citations

This map shows the geographic impact of Eng Huat Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eng Huat Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eng Huat Tan more than expected).

Fields of papers citing papers by Eng Huat Tan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eng Huat Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eng Huat Tan. The network helps show where Eng Huat Tan may publish in the future.

Co-authorship network of co-authors of Eng Huat Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Eng Huat Tan. A scholar is included among the top collaborators of Eng Huat Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eng Huat Tan. Eng Huat Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Soo, Ross A., Eng Huat Tan, Hidetoshi Hayashi, et al.. (2022). Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. Lung Cancer. 169. 67–76. 13 indexed citations

Tan, Sze Huey, Wan‐Teck Lim, Eng Huat Tan, et al.. (2019). Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). PLoS ONE. 14(11). e0224665–e0224665. 21 indexed citations

Park, Keunchil, Eng Huat Tan, Li Zhang, et al.. (2017). P3.02b-044 Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7. Journal of Thoracic Oncology. 12(1). S1214–S1214. 1 indexed citations

Park, Keunchil, Eng Huat Tan, Li Zhang, et al.. (2017). OA23.05 First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7. Journal of Thoracic Oncology. 12(1). S335–S336. 1 indexed citations

Tan, Eng Huat, Wan‐Teck Lim, Ravindran Kanesvaran, et al.. (2016). EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. Journal of Thoracic Oncology. 12(3). 529–538. 61 indexed citations

Klughammer, Barbara, Wolfram Brugger, Federico Cappuzzo, et al.. (2016). Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. Journal of Thoracic Oncology. 11(4). 545–555. 78 indexed citations

Zhang, Zhenxian, Eng Huat Tan, Mei‐Kim Ang, et al.. (2016). Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules. PLoS ONE. 11(5). e0154316–e0154316. 14 indexed citations

Iyer, N. Gopalakrishna, Daniel Shao-Weng Tan, Weining Wang, et al.. (2015). Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10‐year update and subset analysis. Cancer. 121(10). 1599–1607. 136 indexed citations

Tan, Eng Huat, Daniel S.W. Tan, Benjamin Haaland, et al.. (2015). Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. Lung Cancer. 88(3). 289–296. 17 indexed citations

10.

Tai, Wai Meng David, Cindy Lim, Whee Sze Ong, et al.. (2015). Do elderly patients benefit from enrollment into Phase I Trials?. Journal of Geriatric Oncology. 6(3). 241–248. 3 indexed citations

11.

Tan, Daniel S.W., Benjamin Haaland, Su Chin Tham, et al.. (2014). Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer. Molecular Cancer. 13(1). 13–13. 46 indexed citations

12.

Ngeow, Joanne, Swan Swan Leong, Fei Gao, et al.. (2009). Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status. Critical Reviews in Oncology/Hematology. 76(1). 53–60. 21 indexed citations

13.

Leong, Swan Swan, Joseph Wee, Sandeep K. Rajan, et al.. (2008). Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5‐fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer. 113(6). 1332–1337. 52 indexed citations

14.

Ramlau, Rodryg, Jaafar Bennouna, Eng Huat Tan, et al.. (2007). A3-05: Phase III study of vinflunine versus docetaxel in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum containing regimen. Journal of Thoracic Oncology. 2(8). S317–S318.

15.

Leong, Swan Swan, Chee‐Keong Toh, Wan‐Teck Lim, et al.. (2007). A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are Elderly. Journal of Thoracic Oncology. 2(3). 230–236. 34 indexed citations

16.

Chang, Alex Y., Purvish M. Parikh, Sumitra Thongprasert, et al.. (2006). Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal of Thoracic Oncology. 1(8). 847–855. 144 indexed citations

17.

Quek, Richard, Soon Thye Lim, & Eng Huat Tan. (2006). Pneumoperitoneum following percutaneous lung biopsy. The Lancet. 368(9549). 1794–1794. 2 indexed citations

18.

Leong, Swan‐Swan, Joseph Wee, Miah Hiang Tay, et al.. (2004). Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma. Cancer. 103(3). 569–575. 57 indexed citations

19.

Leong, Swan Swan, Kam Weng Fong, Yew Kwang Ong, et al.. (2004). Chemo-radiotherapy for stage III unresectable non-small cell lung cancer—long-term results of a prospective study. Respiratory Medicine. 98(11). 1080–1086. 6 indexed citations

20.

Leong, Swan Swan, et al.. (2001). Recurrent nasopharyngeal carcinoma presenting as diffuse dermal lymphatic infiltration in the neck: Three case reports. Head & Neck. 23(2). 160–165. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact